S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The Collapse of 2022 Has Begun (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The Collapse of 2022 Has Begun (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The Collapse of 2022 Has Begun (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The Collapse of 2022 Has Begun (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:CRTX

Cortexyme - CRTX News Today

$1.33
-0.07 (-5.00%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.29
$1.46
50-Day Range
$1.25
$2.37
52-Week Range
$1.78
$40.66
Volume
132,774 shs
Average Volume
620,672 shs
Market Capitalization
$40.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50
Get Cortexyme News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.



CRTX Media Mentions By Week

CRTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRTX
News Sentiment

0.00

0.83

Average
Medical
News Sentiment

CRTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRTX Articles
This Week

0

4

CRTX Articles
Average Week

SourceHeadline
businesswire.com logoCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business Wire
businesswire.com - July 27 at 3:47 PM
businesswire.com logoCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business Wire
businesswire.com - July 27 at 3:47 PM
finance.yahoo.com logoCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo Finance
finance.yahoo.com - July 27 at 10:45 AM
finance.yahoo.com logoCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
finance.yahoo.com - July 27 at 10:44 AM
finance.yahoo.com logoCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
finance.yahoo.com - July 27 at 10:44 AM
streetinsider.com logoCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.com
streetinsider.com - July 22 at 10:41 PM
benzinga.com logoCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - Benzinga
benzinga.com - June 21 at 11:52 AM
nasdaq.com logoCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - Nasdaq
nasdaq.com - June 21 at 11:52 AM
finance.yahoo.com logoCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
finance.yahoo.com - June 21 at 11:52 AM
businesswire.com logoCortexyme Appoints June Bray to its Board of Directors - Business Wire
businesswire.com - June 13 at 3:34 PM
finance.yahoo.com logoCortexyme Appoints June Bray to its Board of Directors - Yahoo Finance
finance.yahoo.com - June 13 at 10:33 AM
finance.yahoo.com logoCortexyme Appoints June Bray to its Board of Directors
finance.yahoo.com - June 13 at 10:33 AM
businesswire.com logoCortexyme Successfully Completes Acquisition of Novosteo - Business Wire
businesswire.com - May 22 at 5:27 PM
nasdaq.com logoThis Is the Worst Type of Credit Card for Most Consumers - Nasdaq
nasdaq.com - May 20 at 5:28 PM
finance.yahoo.com logoPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo Finance
finance.yahoo.com - May 20 at 9:21 AM
finance.yahoo.com logoCortexyme Successfully Completes Acquisition of Novosteo - Yahoo Finance
finance.yahoo.com - May 20 at 9:21 AM
finance.yahoo.com logoCortexyme Appoints Dr. Philip Low to Its Board of Directors
finance.yahoo.com - May 20 at 9:21 AM
nasdaq.com logoPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - Nasdaq
nasdaq.com - May 13 at 3:32 PM
finance.yahoo.com logoCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases - Yahoo Finance
finance.yahoo.com - May 12 at 10:14 AM
finance.yahoo.com logoCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
finance.yahoo.com - May 12 at 10:14 AM
streetinsider.com logoForm 10-Q Cortexyme, Inc. For: Mar 31 - StreetInsider.com
streetinsider.com - May 11 at 1:09 AM
streetinsider.com logoCortexyme Announces Agreement to Acquire Novosteo - StreetInsider.com
streetinsider.com - May 11 at 1:09 AM
bizjournals.com logoTuesday Digest: Prologis attempts hostile buyout of Duke; Salesforce's latest buy - San Francisco Business Times - The Business Journals
bizjournals.com - May 10 at 2:57 PM
finance.yahoo.com logoCortexyme Announces Agreement to Acquire Novosteo
finance.yahoo.com - May 10 at 9:56 AM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm
benzinga.com - May 6 at 9:43 PM
finance.yahoo.com logoIs Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - May 6 at 3:29 PM
benzinga.com logoThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Appl - Benzinga
benzinga.com - May 3 at 1:35 PM
benzinga.com logoCortexyme Announces Further Layoffs, Chief Medical Officer Leaves
benzinga.com - May 3 at 10:17 AM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm
benzinga.com - May 1 at 9:38 PM
benzinga.com logoCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - Benzinga
benzinga.com - April 28 at 1:44 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX - Benzinga
benzinga.com - April 23 at 9:08 PM
globenewswire.com logoBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm - GlobeNewswire
globenewswire.com - April 15 at 9:03 PM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Medallion, Cortexyme, SelectQuote, and Corcept and Encourage - Benzinga
benzinga.com - April 11 at 10:31 AM
globenewswire.com logoBragar Eagel & Squire, PC Is Investigating Medallion, - GlobeNewswire
globenewswire.com - April 10 at 11:33 PM
globenewswire.com logoHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm - GlobeNewswire
globenewswire.com - March 28 at 6:26 PM
globenewswire.com logoBragar Eagel & Squire, PC Is Investigating Sea, - GlobeNewswire
globenewswire.com - March 27 at 12:11 PM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Sea, Cortexyme, and RBB and Encourages Investors to Contact the Firm
benzinga.com - March 25 at 9:49 PM
benzinga.com logoCRTX SHAREHOLDER ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Cortexyme, Inc. Investors with Loss - Benzinga
benzinga.com - March 22 at 4:45 AM
benzinga.com logoCortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain - Benzinga
benzinga.com - March 22 at 4:45 AM
finance.yahoo.com logoCortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
finance.yahoo.com - March 21 at 1:10 PM
globenewswire.com logoCRTX INVESTOR ALERT: Hagens Berman, National Trial - GlobeNewswire
globenewswire.com - March 19 at 6:27 PM
benzinga.com logoCRTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm
benzinga.com - March 19 at 10:59 AM
businesswire.com logoCortexyme to Present New GAIN Trial Data at AD/PD 2022 - Business Wire
businesswire.com - March 16 at 8:57 AM
finance.yahoo.com logoCortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
finance.yahoo.com - March 15 at 12:55 PM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Cortexyme, FAT Brands, Koppers, and RBB and Encourages Investors to Contact the Firm
benzinga.com - March 14 at 10:18 PM
globenewswire.com logoBragar Eagel & Squire, PC Is Investigating Cortexyme, FAT Brands, Koppers, and RBB and Encourages Investors to Contact the Firm - GlobeNewswire
globenewswire.com - March 14 at 9:54 PM
benzinga.com logoCortexyme to Present New GAIN Trial Data at AD/PD 2022 - Benzinga - Benzinga
benzinga.com - March 14 at 4:53 PM
finance.yahoo.com logoCortexyme to Present New GAIN Trial Data at AD/PD 2022 - Yahoo Finance
finance.yahoo.com - March 14 at 8:49 AM
finance.yahoo.com logoCortexyme to Present New GAIN Trial Data at AD/PD 2022
finance.yahoo.com - March 14 at 8:49 AM
finance.yahoo.com logoNordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting - Yahoo Finance
finance.yahoo.com - March 9 at 9:20 AM
Get Cortexyme News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CRTX) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.